

STATE-OF-THE-ART MANUFACTURING FACILITY COMMENCES GMP PRODUCTION FOR A RANGE OF NOVEL IMMUNOTHERAPEUTICS

Eden Biodesign announces full operation of its state-of-the-art GMP manufacturing facility

Liverpool, UK; 21 May, 2007: Eden Biodesign Ltd, the fast-growing biopharmaceutical development and manufacturing services specialist announced today that it has been awarded a licence by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture Investigational Medicinal Products (IMPs) at its new state-of-the art facility in Liverpool, UK.

The UK National Biomanufacturing Centre operated by Eden Biodesign came on-line for process and analytical development in May 2006. The MHRA inspection took place earlier this year to certify Eden's processes and facilities as having reached the international Good Manufacturing Practices (cGMP) standard. The new license will provide legal authority for Eden to manufacture biopharmaceutical drug substances under contract for clients for use in EU clinical trial sites.

Dr Crawford Brown, CEO of Eden Biodesign commented: "Eden is now fully on track and able to deliver a full range of services for the production of mammalian, microbial and virus-based experimental medicines for a worldwide client base."

He added "We are particularly delighted as we designed the UK Biomanufacturing Centre that we operate and the MHRA license is recognition of our expertise in process development, cGMP manufacturing for clinical studies of new medicines and analytical development".


Following the successful inspection Eden recently announced that it will provide ImmBio, based in Cambridge (UK), with a range of development and manufacturing services to rapidly advance their leading influenza vaccine forward towards a Clinical Trial Application.

Eden has also started to supply cGMP clinical manufacturing services to Onyvax, a private UK Biotech, for its ovarian cancer vaccine and extended a project with Silence Therapeutics plc (formerly SR Pharma plc), delivering the listed UK biotech with a whole cell microbial immunotherapeutic for the treatment of asthma and as a therapeutic in cancer and tuberculosis.

Ends

For further information please contact:

Stéphanie Monfront, De Facto Communications Ltd +44 (0)20 7861 3838
Email s.monfront@defacto.com



Notes to editors:

Eden Biodesign

Eden Biodesign is a fast-growing biopharmaceutical development and manufacturing services specialist that works with biotech clients across Europe, the USA and Asia. It is committed to excellent service delivery and has the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that produce clinically and commercially valuable products driven by a total focus on project management, meticulously planned and delivered. For further information please visit www.edenbiodesign.com.

The National Biomanufacturing Centre

The £34.25 million National Biomanufacturing Centre which was officially opened in November 2006, is a Government-funded initiative led by the Northwest Regional Development Agency (NWDA) additionally funded through the European Regional Development Fund (ERDF) and the Department of Trade and Industry (DTI) and aims to establish England's Northwest as one of the foremost biomanufacturing centres in Europe.

The centre provides the expertise and facilities to support new and existing biotechnology companies, offering product development services designed to fill in the skill and resource gaps that exist within these organisations. It also provides training in biomanufacturing and analytical sciences, delivering the skilled workforce required to expand the UK biopharmaceutical sector.

There is also an Access Fund of nearly £3 million funded by the Department of Trade and Industry and the European Regional Development Fund, which is available to qualifying small-to-medium companies and academic groups in the biotechnology sector to assist them in purchasing development and clinical manufacturing services from the Centre.